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Comprehensive analysis of 
transcriptome and metabolome 
analysis in Intrahepatic 
Cholangiocarcinoma and 
Hepatocellular Carcinoma
Yoshiki Murakami1, Shoji Kubo2, Akihiro Tamori1, Saori Itami1, Etsushi Kawamura1, 
Keiko Iwaisako3, Kazuo Ikeda4, Norifumi Kawada1, Takahiro Ochiya5 & Y-h Taguchi6
Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are liver originated 
malignant tumors. Of the two, ICC has the worse prognosis because it has no reliable diagnostic 
markers and its carcinogenic mechanism is not fully understood. The aim of this study was to 
integrate metabolomics and transcriptomics datasets to identify variances if any in the carcinogenic 
mechanism of ICC and HCC. Ten ICC and 6 HCC who were resected surgically, were enrolled. 
miRNA and mRNA expression analysis were performed by microarray on ICC and HCC and their 
corresponding non-tumor tissues (ICC_NT and HCC_NT). Compound analysis was performed using 
capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS). Principle component analysis 
(PCA) revealed that among the four sample groups (ICC, ICC_NT, HCC, and HCC_NT) there were 14 
compounds, 62 mRNAs and 17 miRNAs with two distinct patterns: tumor and non-tumor, and ICC 
and non-ICC. We accurately (84.38%) distinguished ICC by the distinct pattern of its compounds. 
Pathway analysis using transcriptome and metabolome showed that several pathways varied 
between tumor and non-tumor samples. Based on the results of the PCA, we believe that ICC and 
HCC have different carcinogenic mechanism therefore knowing the specific profile of genes and 
compounds can be useful in diagnosing ICC.
Intrahepatic cholangiocarcinoma (ICC) is the second most common hepatic cancer and accounts for 
10–25% of all hepatic malignant tumors1,2. Hepatocellular carcinoma (HCC) represents the major histo-
logical subtype of primary liver malignancies, accounting for 70% to 85% of the total liver cancer bur-
den3. Most cases of HCC (75% to 90%) are found in patients with liver cirrhosis resulting from chronic 
hepatitis B or C infection, alcoholic injury, and recently in non-alcoholic steatohepatitis (NASH)4,5. ICC 
is labeled as a malignant tumor arising from the peripheral intrahepatic bile duct epithelium1. High 
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risk factors associated with ICC includes being male6 being over age 657, and having primary sclerosing 
cholangitis (PSC)8, biliary duct cysts9, hepatolithiasis10, and chemical toxin overload11. It was also previ-
ously reported that genetically impaired biliary excretion of phospholipids is an underlying mechanism 
of ICC12,13. Metabolomic investigations support this view, as lower phosphatidylcholine and elevated 
glycine- and taurine-conjugated bile acids have been reported in the bile of ICC patients14,15.
Several pathways and genetic alternations have been associated with ICC development. For exam-
ple, aberrant glucose and lipid metabolism as well as 15-hydroxyprostaglandin dehydrogenase-mediated 
15-keto-prostaglandin E2 signaling cascade inhibited ICC cell growth via peroxisome proliferator-activated 
receptor-gamma, Smad2/3, and TAP63 pathway16. The endocannabinoid anandamide exerts an 
anti-proliferative effect on ICC through one of the cannabinoid G-protein coupled receptor 55, and 
by stabilizing lipid rafts. This allows for the recruitment and activation of the Fas receptor complex17. 
Simvastatin is known to induce ICC cell death by disrupting Rac1/lipid raft co-localization and by 
depressing Rac1 activity18. Aberrant miRNA expression has also been associated with ICC; notably, 
miR-21 has been implicated in cell proliferation, apoptosis, metastasis, and migration19,20. let-7a was 
also found to be up-regulated in ICC and contributes to the survival of cholangiocytes via enforced IL-6 
activity21,22.
ICC is characterized by histological observations of dissected tumors. It is difficult to conclude whether 
ICC is truly derived from cholangiocytes as it was reported that patients with hepatitis C virus infection 
often develop ICC, suggesting that ICC is derived from transformed hepatocytes23. Several reports have 
suggested that Notch activation is critical for hepatocytes to convert into biliary lineage cells during the 
onset of ICC and its subsequent malignancy and progression. In these said studies therefore, ICC was 
generated by biliary lineage cells derived from hepatocytes, rather than from cholangiocytes24. ICC is 
known to have a poorer survival outcome than HCC mainly due to the advanced tumor stage of patients 
with intrahepatic metastasis at presentation and early postoperative recurrence25. New biomarkers that 
can detect ICC, especially in its early stages, and that can help clarify the mechanism of ICC are needed 
to increase the survival rate for ICC patients.
In this study, we performed a comprehensive analysis using transcriptome and metabolome to dis-
cover (1) if there is a difference in the carcinogenic process between ICC and HCC, and (2) accurate and 
sensitive molecular markers to diagnose ICC.
Result
Variable selection using principal component. Each mRNA, miRNA or compound taken from 
the thirty two samples (10 pairs of ICC and ICC-NT, and 6 pairs of HCC and HCC-NT) (Supplementary 
Table 1), was considered as a point in a 32 dimensional space and embedded in a low dimensional 
space using principal component analysis (PCA). Figure 1 shows the hierarchical clustering of the prin-
cipal components (PCs). The vertical axis exhibits the negative correlation coefficients used to define 
the distance measures of the clusters. Since each CXjk (j,k = 1, 2,,, 32) is a composite of the 32 samples, 
CXk = (CX1k,CX2k,…,CX32k ) was also expressed as 32-dimensional vectors (see supplementary method). 
To reiterate, the primary aim of this study was to perform an integrated analysis of compounds, mRNA, 
and miRNA, to identify those that are related to ICC and HCC. The numbers attached to PCs repre-
sent the order of PCs while smaller numbers indicate larger contributions to overall variances. Using 
Figure 1. Hierarchical Clustering using correlation coefficients. Hierarchical clustering of 96 PCs: 
consisting of 32 PCs each obtained from mRNAs, miRNAs and compounds. Each PC consists of 32 
dimensional vectors with 32 elements, each of which corresponds to the contribution of each sample to 
each PC. The correlation coefficients between PCs were computed using these 32 elements. On the Vertical 
axis are absolute negative correlation coefficients that are used as distance for hierarchical clustering (lower 
pairs have larger absolute correlations). Red rectangle indicates 5PCs which were chosen by hierarchical 
clustering.
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Unweighted Pair Group Method with Arithmetic Mean (UPGMA) we performed separate PCA for 
compounds, mRNA and miRNA. The PCs were chosen based on the following two criteria: (1) The PC 
cluster should be located in the lower right position, in other words, the absolute value of the correlation 
coefficient should be the largest. (2) k of selected CXk should be as small as possible, since a smaller k 
indicates more contributions. Five PC (loading)s fulfilled these criteria: PC3_comp (PC3_ compound), 
PC1_mRNA, PC2_mRNA, PC1_miRNA and PC2_miRNA (Fig. 3).
In order to validate the correlation of each selected PC, we performed a scatter plot analysis (Fig. 2). 
A comparison was done of the expression patterns of compound, miRNA, and mRNA among ICC, 
ICC-NT, HCC, and HCC-NT. As expected ICC and HCC had expressions that were markedly distinct 
from their non-tumor (NT) counterpart; however, the difference between ICC and ICC-NT was greater 
than HCC and HCC-NT (Fig. 2). Each row and column corresponds to the PCs displayed diagonally. For 
example, the scatter plot in the third row and second column is between PC1_mRNA and PC2_mRNA. 
Open rectangles in the second row and third column indicate correlation coefficients (upper numerical 
value) and their P-values (lower numerical value) associated with the corresponding scatter plots.
Next, to quantitatively confirm that selected PCs were significantly distinct among HCC, ICC, 
HCC-NT and ICC-NT, we performed the following categorical regression analysis.
= + δ + δ + δ + δ. − − . . − − .C C C C CCX j
k
X0 ICC ICC j ICC NT ICC NT j HCC HCC j HCC NT HCC NT j
Figure 2. Scatter diagram. Lower triangle: Scatter plot between five PCs (a) PC3_comp, (b) PC1_mRNA, 
(c) PC2_mRNA, (d) PC1_miRNA, and (e) PC2_miRNA, selected based on the hierarchical clustering shown 
in Fig. 1. Each row and column corresponds to the PC displayed diagonally. Open rectangle in the second 
row and third column indicates the correlation coefficients (upper numerical value) and their P-values 
(lower numerical value) associated with the corresponding scatter plots.
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Here δ a,i takes one if the i-th sample is equivalent to category a (a represents ICC, ICC-NT, HCC, or 
HCC-NT), otherwise it had a value of zero. CXik reflects the contribution of the sample i to the kth prin-
cipal component. We employed categorical regression instead of ordinary multivariate analysis because 
the order and magnitude among the four groups (ICC, ICC/-NT, HCC, and HCC-NT) was unknown. 
The genetic distance between ICC and ICC-NT appeared larger than between HCC and HCC-NT (Fig 3). 
All together, this data suggests that we successfully selected PCs that accurately distinguished two distinct 
patterns (tumor/non-tumor and ICC/non-ICC) among the four groups. More detailed methodological 
and theoretical background can be found in our previous publications26,27 and supplementary methods.
Figure 3. Box plot in 5 PCA. Box Plot of PCs is shown in Fig. 2. The sample contribution to each PC 
are shown using boxplot classified based on four sample classes. The correlation coefficients used for the 
hierarchical clustering tree represented in Fig. 1 and shown in the upper triangle in Fig. 2 are for the 
distances found among the five plots. Vertical line represents genetic distance. Red dots are depicted as 
measured value of each probe after normalization. P values are shown in a scatter plot (P value of PC3_
comp, PC1_mRNA, PC2_mRNA, PC1_miRNA, and PC2_miRNA, correspond to 8.68e-03, 1.69e-02, 3.98e-
06, 4.74e-02, and 9.42e-03, respectively).
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Selection of ICC related compound, mRNA, and miRNA. We used PCA based unsupervised 
FE to select the ICC related compounds, mRNA, and miRNA28. Results from scatter plots in five PCs, 
showed that each of the four groups had compound levels or gene expression patterns that were dis-
tinct. Figure  4 shows two-dimensional embedding of mRNA/miRNA spanned by PCXi1 and PCXi2 
and compounds spanned by PCXi2 and PCXi3 all obtained by PCA (see supplementary method). Each 
circle in Fig. 4 corresponds to an individual compound detected by CE-TOFMS or individual mRNA/
miRNA expression (probe) on microarray plate. Red circles are “outliers” selected for further analysis: 
compounds along PC3, mRNA along PC1 and miRNAs along PC1 and PC2. In total 14 outlying com-
pounds, 62 mRNAs, and 17 miRNAs, were selected since they had larger contributions towards the 5PCs 
(red circle in figure selection) (Fig. 4), (Supplementary Table 2, 3, 4).
Fourteen compounds (Fig.  5 and Supplementary Table 2), were selected that could separately dis-
tinguish each of our four sample groups. For example, Glycerol 3− phosphate, Succinic acid and 
Glycerophosphocholine were differentially expressed in the tumor (HCC and ICC) and non-tumor 
(HCC-NT and ICC-NT) population. A distinction between tumor and non-tumor samples was also 
seen in PC3 of compound (Fig.  3). Thus we surmise that it is due to these three compounds that a 
distinction can be made between tumors and non-tumors. On the other hand, four amino acids (Lys, 
Pro, Leu and IIe) were more diversely expressed in ICC/ICC-NT than in HCC and HCC-NT. Since this 
was also observed in PC3 (Fig.  3), we believe these four amino compounds are primarily responsible 
for ICC/ICC-NT having a larger genetic distance than HCC and HCC-NT. Hypoxanthine and Taurine 
were the only compounds that had distinct expressions that differentiated ICC from HCC, HCC-NT and 
ICC-NT which suggests that these two compounds allowed ICC to be distinguished from other tumor 
and non-tumor samples.
Multiple probes can be mapped to a singular gene in order to increase sensitivity and specificity; sev-
eral mRNAs (APOA1, MTRNR2L2, and RPS2) in this study had multiple probes resulting in a total of 
67 probes for 62 mRNAs. Abbreviations for genes are shown in Table S3. Among these 62 mRNAs (Fig. 6 
and Supplementary Table 3), there were several groups that share similar expression with compounds. 
For example, HRP, HP, APOA1, ALDOB, ITIH4, ORM1, SERPINA1, HRG, and MT2A are mRNAs 
that express differentially between tumors (HCC and ICC) and non-tumors (ICC-NT and HCC-NT), 
while ALB, APOE, RBP4, TTR, AMBP, APOA2, APOC3, APOH, CES1 and APOC1 are expressed in 
ICC distinctly from the other three samples. We observed two varying patterns among mRNA: one is 
the distinction between tumors and non-tumors reflected by PC2_mRNA; the other is the distinction 
between ICC and the other three groups, which are reflected by PC1_mRNA (Fig. 3).
Similarly, two clear distinctions were observed between tumors and non-tumors, and ICC and 
non-ICC among 17 miRNAs (Fig.  7 and Table  S4). The former group consisted of miR-21-5p, miR-
122-5p, miR-451a, and miR-4286, while let-7b-5p and miR-16-5p fell in the latter. These two tendencies 
were also observed in PC2 and PC1 in miRNAs (Fig. 3).
ICC related carcinogenetic pathway. In order to clarify the biological significance of the selected 
compounds and genes Integrated Molecular Pathway Level Analysis (IMPaLA) (http://impala.molgen.
mpg.de) was used to calculate the pathway enrichment of the compounds and mRNA chosen from 
pathways, such as KEGG and REACTOME as well as other data sets. The list of pathways with P values 
for which multiple comparisons and adjustments were carried out is shown (p < 0.05) in supplementary 
Table 5 and 6.
In the heatmap in Supplementary Fig. 1 and 2 the black boxes represent either compound or 
mRNAs. Similar pathways were classified under one color cluster using UPGMA. For example, C00819 
Figure 4. Embedding of compound, mRNA, and miRNA. (a) Two-dimensional embedding of compounds 
spanned by PC2 and PC3. (b) Two-dimensional embedding of mRNA spanned by PC1 and PC2. (c) Two 
dimensional embedding of miRNA spanned by PC1 and PC2. We chose compounds, mRNA and miRNAs 
as “outliers” for further analysis.
www.nature.com/scientificreports/
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(Glutamine) contributes to D-glutamine and D-glutamate metabolism. The largest cluster (red) rep-
resents pathways related to tRNA synthesis (tRNA charging, tRNA aminoacylation, Cytosolic tRNA 
aminoacylation, Mitochondrial tRNA amicoacylation, Aminoacyl-tRNA biosynthesis), and amino acid 
synthesis (glutathione synthesis and recycling, amino acid transport across the plasma membrane, amino 
acid and oligopeptide SLC transporters, transport of inorganic cations/anions and amino acids/oligo-
peptide). The green cluster shows lipoprotein related pathways: metabolism of lipids and lipoproteins, 
acetylcholine Synthesis, glycerophospholipid metabolism, phospholipid metabolism, and hydrolysis of 
LPC (Supplementary Fig. 1).
In the mRNA analysis performed using DIANA-miRPath (http://diana.imis.athena-innovation.gr/
DianaTools/index.php?r= mirpath/index), the yellow cluster represents the lipoprotein related pathways 
(PPAR signaling pathway, HDL− mediated lipid transport, lipoprotein metabolism, lipid digestion_ mobi-
lization_ and transport, statin pathway, chylomicron− mediated lipid transport, scavenging of heme from 
Figure 5. Box plot of selected compounds. Amount of 14 compounds used to discriminate between 
tumor (ICC and HCC) and non-tumor (ICC_NT and HCC_NT) or between ICC and non-ICC (ICC-NT, 
HCC, and HCC-NT). Left vertical axis shows the amount of compound. Red dots are depicted as measured 
value of each probe after normalization. Each p-value is indicated in Table S2. XC00061 is only known as 
Pubchem accession number (http://www.ncbi.nlm.nih.gov/pccompound). Unknown: neither the name of 
component nor the Pubchem accession number is known.
www.nature.com/scientificreports/
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plasma, binding and uptake of ligands by scavenger receptors, FOXA2 and FOXA3 transcription factor 
networks). The red cluster shows the transcription related pathways including the tRNA relation pathway 
(activation of the mRNA upon cap− binding, ribosomal scanning and start codon recognition, peptide 
chain elongation, eukaryotic translation elongation, metabolism of RNA, metabolism of mRNA, ribo-
some, eukaryotic translation initiation, cap− dependent translation initiation, SRP− dependent cotrans-
lational protein targeting to GTP hydrolysis and joining of the 60S ribosomal subunit, L13a− mediated 
translational silencing of ceruloplasmin 3− UTR− mediated translational regulation) (Supplementary 
Fig. 2).
Pathway analysis of the validated miRNAs using DIANA-miRPath pointed to 62 cancer-related 
pathways (p < 0.05). RNA synthesis related pathway (RNA transport, Ribosome biogenesis in eukary-
otes, Ribosome, RNA polymerase, Aminoacyl-tRNA biosynthesis) and glucose-lipid synthesis pathway 
(Adipocytokine signaling pathway, Insulin signaling pathway) were found to be associated with ICC 
carcinogenesis (Supplementary Table 7).
Diagnosing ICC using compounds and miRNA expression pattern. We attempted to identify 
diagnostic biomarkers for ICC. We used leave one out cross validation (LOOCV) to classify samples into 
three groups: ICC, HCC, and non-tumorous. Using the profile of 14 compounds (Supplementary Table 
2), we classified ICC, HCC and non-tumorous tissue with 84.38% accuracy (Table  1). ICC was distin-
guished from the other 3 sample groups with 78.13% of accuracy (Table 1) using the expression profile 
of 17 miRNAs (Supplementary Table 4). However mRNA expression combined with the characteristics 
Figure 6. Box plot of selected mRNAs. Expression pattern of 62 mRNA used to discriminate between 
tumor (ICC and HCC) and non-tumor (ICC_NT and HCC_NT) or between ICC and non-ICC (ICC-NT, 
HCC, and HCC-NT). In cases where there are multiple probes for one mRNA, pleural box plots with the 
same mRNA are listed. Vertical left axis shows the expression level of mRNAs. Red dots are depicted as 
measured value of each probe after normalization. P-values are indicated in Table S3.
www.nature.com/scientificreports/
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of the compounds or miRNA expression profile was unable to diagnose ICC with high accuracy (date 
not shown).
Discussion
In this study, we performed an integrated analysis of transcriptome and metabolome to clarify the mech-
anism of ICC and HCC carcinogenesis and to discover novel diagnostic markers for ICC. Using five PCs 
comprising of 14 compounds, 62 mRNAs and 17 miRNAs, we observed two distinct patterns: tumor/
non-tumor, and ICC/non-ICC.
It was difficult to uncover the carcinogenetic mechanism for ICC although each gene expression and 
the level of each compound could be determined. We used Integrated Molecular Pathway Level Analysis 
Figure 7. Box plot of selected miRNAs. Expression pattern of 17 miRNAs used to discriminate between 
tumor (ICC and HCC) and non-tumor (ICC_NT and HCC_NT) or between ICC and non-ICC (ICC-NT, 
HCC, and HCC-NT). Vertical left axis shows miRNA expression levels. P-values are indicated in Table S4.
www.nature.com/scientificreports/
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(IMPaLA) to analyze compounds and mRNA and the DIANA-miRPath for miRNA analysis. Aberrant 
expression of mRNA in ICC was related to aberrant tRNA metabolism, amino acid metabolism, and 
lipoprotein metabolism (supplementary Fig. 1). Elevated compound levels coincided with lipoprotein 
and tRNA metabolism (Supplementary Fig. 2). Finally a connection was found between ICC and several 
miRNA related pathways namely: RNA transport, ribosome biogenesis in eukaryotes, protein export, 
RNA polymerase, and Aminoacyl-tRNA biosynthesis. Although we did not find that lipoprotein to be a 
miRNA related pathway, it had a strong connection to miRNA. However lipid metabolism, amino acid 
metabolism, and RNA metabolism are associated with ICC formation.
In our analysis, there were two primary pathways implicated in ICC. The first is lipid and glucose 
related pathway. A large number of metabolomic changes were observed in HCC that were relative 
to cirrhosis or to control subjects (review in29). Lipids, bile juice secretion, and ICC were found to be 
closely inter-related. Taurocholate and phosphatidylcholine have no effect on apolipoprotein B (apo B) 
secretion but has been known to significantly increase the basolateral secretion of APOA130. Elevated 
taurine level in ICC in this study coincides with previous reports14,15. Signs of metabolic remodeling has 
been detected by metabolomics in the livers of HCC patients, namely a decrease in glucose, citrate, and 
glycerol 3-phosphate coupled with an increase in pyruvate (signs of the Warburg effect31), and a switch 
from mitochondrial respiration to cytosolic aerobic glycolysis32,33. In our study, down regulated amino 
acid metabolism and up regulated G-3-P metabolism were observed in both HCC and ICC. Thus, met-
abolic reprogramming in HCC and ICC appeared to exhibit a modest Warburg shift towards glycolytic 
metabolism and a major upregulation of fatty acid catabolism in some tumor types.
The second pathway implicated in ICC is the tRNA related pathway. Aminoacyl-tRNA synthetases 
(ARSs) are essential and ubiquitous ‘house-keeping’ enzymes responsible for charging amino acids to 
their cognate tRNAs with a high fidelity and providing the substrates for global protein synthesis34. 
Defects in either canonical or noncanonical ARS functions can cause or contribute to human diseases. 
ARSs suspected involvement in several types of cancer through aberrant expression and interactions have 
been previously reported35,36. Our analysis indicated that in addition to ARS, many RNA regulated path-
ways were involved in ICC. Many therapeutic reagents that are highly potent also produce adverse side 
effects such as non steroidal anti-inflammatory drugs associated with increased risk of coronary heart 
disease, and anti-VEGF-A inhibitors implicated in the disruption of blood vessel maintenance. Novel 
cancer drug related to ARS might provide a new set of physiologic extracellular or intracellular path-
ways as the basis for developing novel therapeutics with minimal side effects. The advantage of applying 
natural secretory or endogenous ARSs (e.g., GARS and EPRS) to clinical use is that they catalyze the 
ligation of amino acids to their cognate tRNAs with a high fidelity. For example, RS and ARS-interacting 
multifunctional proteins participate in the formation of Glioblastoma multiforme, therefore these com-
pounds are possible candidates to be used in the development of innovative drugs36. Another candidate is 
human LARS which has the ability to correct mitochondrial dysfunctions caused by tRNALeuUURA3233G 
mutation-related neurodegenerative disorder in MELAS syndrome37.
Several reports on the origin of hepatocyte and cholangiocyte have led to the understanding that 
hepatoblasts are bipotent precursors that develop into either hepatocyte (the main epithelial cells in the 
liver) or cholangiocyte (the epithelial cells lining the intrahepatic biliary ducts). The formation of hepat-
ocyte and cholangiocyte is temporally and spatially separated, which suggests that localized inducers or 
repressing mechanisms operate to direct the fate of both38. Hepatocytes can change into biliary lineage 
cells when intrahepatic bile duct regeneration is induced, but cholangiocytes cannot proliferate owing to 
toxic influences39. Hepatocytes can transdifferentiate into biliary lineage cells regardless of their position 
in the hepatic lobule. The location of lineage-converting hepatocytes is likely decided by the nature of 
the toxins used. Notch-mediated conversion of hepatocytes into biliary lineage cells accelerates ICC 
formation24. Moreover non-B non-C HCC patients were chosen for this study as there would be are 
no influenced by gene expression or the amount of compounds in hepatic virus B or C infection. In 
Result
non-tumor HCC ICC
A. Using profiling of compounds
 Prediction
non-tumor 14 0 2
HCC 0 5 0
ICC 2 1 8
B. Using miRNA expression pattern
 Prediction
non-tumor 13 1 1
HCC 2 4 1
ICC 1 1 8
Table 1.  Classifying CC, HCC and non-tumor.
www.nature.com/scientificreports/
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this study, embryological similarity between cholangiocyte and hepatocyte coincided with the similarity 
between the carcinogenic mechanism of ICC and HCC. Moreover, the difference in clinical malignancy 
grade between ICC and HCC also coincided with the genetic differences between ICC and HCC.
In this study we were able to diagnose ICC with high accuracy using molecular information from 
the tumor tissue. Specifically, the serum values of AFP and DCP, and CEA and CA19-9 were used to 
distinguish HCC and ICC, respectively. However, the specificity and sensitivity for diagnosing HCC by 
AFP and DCP, and diagnosing ICC by CEA and CA19-9 were not satisfactory. Pathological diagnosis 
of ICC was complicated because poorly differentiated HCC and ICC had similar pathological findings; 
as well, there was a type of HCC which had the characteristics of both ICC and HCC. ICC could be 
diagnosed using miRNA or compounds with an approximate 80% accuracy. To our knowledge this is the 
first report that has identified a highly specific tumor marker for ICC. Although our sample was not as 
large as would have been ideal, integrating transcriptome and metabolome analysis creates more reliable 
results than performing a single analysis such as transriptome or metabolome. We propose that in the 
future a similar study be done with a larger sample.
In conclusion, we found that there were several common pathways involved in ICC and HCC for-
mation and the clinical and genetic malignant potential of ICC was higher than HCC. Using PCA we 
also revealed that ICC could be distinguished from non-ICC using the biomarkers we identified. These 
mRNA, miRNAs, and compounds are a promising start to uncovering novel biomarkers that may lead 
to therapeutic applications in the future.
Methods
Sample preparation. Ten ICC and six HCC samples were obtained by surgical resection 
(Supplementary Table 1). We created four groups using the ICC/HCC samples and their respective sur-
rounding non-tumor tissues. ICC and HCC were diagnosed using tumor markers (AFP, CEA, CA19-9 
and DCP), CT and pathological examination. All samples were negative for HBs-Ag and anti-HCV. All 
patients provided written informed consent, and the Faculty of Medicine Ethics Committee of Osaka 
City University approved all aspects of this study in accordance with the Helsinki Declaration.
RNA preparation and miRNA. Total RNA from tissue samples was prepared using a mirVana 
miRNA extraction Kit (Ambion, Austin, TX, USA) according to the manufacturer’s instruction. To detect 
miRNA, 100 ng of RNA was labeled and hybridized using the Human microRNA Microarray Kit (Rel. 
12.0) (Agilent Technologies, CA, USA) according to the manufacturer’s protocol for use with Agilent 
microRNA microarrays Version 1.0. Hybridization signals were detected with Agilent DNA microar-
ray scanner G2505B and the scanned images were analyzed using Agilent feature extraction software 
(v10.10.1.1). All data were deposited in NCBI’s Gene Expression Omnibus and are accessible through 
GEO Series accession number GSE57555.
mRNA microarray. To detect mRNA, 100 ng of RNA was labeled and hybridized using the SurePrint 
G3 Human GE Microarray Kit (Ver 2.0) (Agilent Technologies, CA, USA) according to the manufac-
turer’s protocol for use with Agilent microRNA microarrays Version 2.0. Hybridization signals were 
detected with Agilent DNA microarray scanner G2539A and the scanned images were analyzed using 
Agilent feature extraction software (v10.10.1.1). All data were deposited in NCBI’s Gene Expression 
Omnibus and are accessible through GEO Series accession number GSE57555.
Measurement of metabolites. After surgical resection, the sample aliquots were frozen in liquid 
nitrogen and then tissue was made into a fine powder using a pestle and mortar in liquid nitrogen. 
Approximately 50 mg of frozen powder tissue was plunged into 1,500 μ L of 50% acetonitrile/Milli-Q 
water containing internal standards (H3304-1002, Human Metabolome Technologies, Inc., Tsuruoka, 
Japan) at 0 °C in order to inactivate the enzymes. The tissue was homogenized thrice at 1,500 rpm for 
120 sec using a tissue homogenizer (Microsmash MS100R, Tomy Digital Biology Co., Ltd., Tokyo, Japan) 
and then the homogenate was centrifuged at 2,300 × g and 4 °C for 5 min. Subsequently, 800 μ L of upper 
aqueous layer was centrifugally filtered through a Millipore 5-kDa cutoff filter at 9,100 × g and 4 °C for 
120 min to remove proteins. The filtrate was centrifugally concentrated and re-suspended in 50 μ L of 
Milli-Q water for CE-MS analysis.
Capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) was carried out using an 
Agilent CE Capillary Electrophoresis System equipped with an Agilent 6210 Time of Flight mass spec-
trometer, Agilent 1100 isocratic HPLC pump, Agilent G1603A CE-MS adapter kit, and Agilent G1607A 
CE-ESI-MS sprayer kit (Agilent Technologies, Waldbronn, Germany). The systems were controlled by 
Agilent G2201AA ChemStation software version B.03.01 for CE (Agilent Technologies, Waldbronn, 
Germany). The metabolites were analyzed using a fused silica capillary (50 μ m i.d. × 80 cm total length), 
with commercial electrophoresis buffer (Solution ID: H3301-1001 for cation analysis and H3302-1021 
for anion analysis, Human Metabolome Technologies) as the electrolyte. The sample was injected at a 
pressure of 50 mbar for 10 sec (approximately 10 nL) in cation analysis and 25 sec (approximately 25 nL) 
in anion analysis. The spectrometer was scanned from m/z 50 to 1,000. Other conditions were as previ-
ously described40–42.
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